Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation

Haematologica

Volumn 89, Issue 2, 2004, Pages 215-232

  Barbui, Tiziano ^a   Barosi, Giovanni ^b   Grossi, Alberto ^c   Gugliotta, Luigi ^d   Liberato, Lucio N ^b   Marchetti, Monia ^b   Mazzucconi, M Gabriella ^e   Rodeghiero, Francesco ^f   Tura, Sante ^g  

^a Divisione di Ematologia   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c CAREGGI UNIVERSITY HOSPITAL   (Italy)

^d Servizio di Ematologia   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f SAN BORTOLO HOSPITAL   (Italy)

^g UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Consensus; Essential thrombocythemia; Practice guidelines; Recommendations

Indexed keywords

ACETYLSALICYLIC ACID; ANAGRELIDE; ANTITHROMBOCYTIC AGENT; BUSULFAN; CLOPIDOGREL; DIPYRIDAMOLE; HYDROXYUREA; INDOMETACIN; MELPHALAN; PEGINTERFERON ALPHA2A; PHOSPHORUS 32; PIPOBROMAN; RECOMBINANT ALPHA INTERFERON; TICLOPIDINE; ALKYLATING AGENT; FIBRINOLYTIC AGENT;

BLEEDING; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGENITAL MALFORMATION; DIARRHEA; DRUG CHOICE; DRUG INDICATION; EDEMA; EVIDENCE BASED MEDICINE; FLU LIKE SYNDROME; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART PALPITATION; HUMAN; LEUKEMIA; MEDICAL SOCIETY; MEDICAL SPECIALIST; PATIENT MONITORING; PATIENT SELECTION; PRACTICE GUIDELINE; REVIEW; SECOND CANCER; SIDE EFFECT; TACHYCARDIA; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOSIS; TREATMENT INDICATION; TREATMENT PLANNING; VALIDATION PROCESS; ACUTE DISEASE; ADULT; AGED; CELL TRANSFORMATION; CHILD; COHORT ANALYSIS; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; DISEASE COURSE; FEMALE; GENETICS; MALE; MIDDLE AGED; MYELOID LEUKEMIA; NEWBORN; PREGNANCY; PREGNANCY OUTCOME; SURVIVAL; THROMBOPHILIA; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; AGED; ALKYLATING AGENTS; CELL TRANSFORMATION, NEOPLASTIC; CHILD; CLINICAL TRIALS; COHORT STUDIES; DISEASE PROGRESSION; EVIDENCE-BASED MEDICINE; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; HYDROXYUREA; INFANT, NEWBORN; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PREGNANCY; PREGNANCY OUTCOME; SURVIVAL ANALYSIS; THROMBOCYTHEMIA, HEMORRHAGIC; THROMBOPHILIA; THROMBOSIS; TREATMENT OUTCOME;

EID: 2942579910     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (114)

1. Kessler CM, Klein HG, Havlik RJ. Uncontrolled thrombocytosis in chronic myeloproliferative disorders. Br J Haematol 1982;50:157-67.
2. Rozman C, Giralt M, Feliu E, Ribio D, Cortes MT. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer 1991;67:2658-63.
3. Bazzan M, Tamponi G, Schinco P, Vaccarino A, Foli C, Gallone G, et al. Thrombosis-free survival and life expectancy in 187 consecutive patients with essential thrombocythemia. Ann Hematol 1999;78:539-43.
4. Jensen MK, de Nully Brown P, Nielsen OJ, Hasselbalch HC. Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area. Eur J Haematol 2000;65:132-9.
5. Thiele J, Kvasnicka HM, Schmitt-Graeff A, Zankovich R, Diehl V. Follow-up examinations including sequential bone marrow biopsies in essential thrombocythemia (ET): a retrospective clinicopathological study of 120 patients. Am J Hematol 2002;70:283-91.
6. Alessandrino EP, Amadori S, Barosi G, Cazzola M, Grossi A, Liberato NL, et al. Evidence and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement of the Italian Society of Hematology. Haematologica 2002;87:1286-306.
7. Harbour R, Miller J, for the Scottish Intercollegiate Guidelines Network Grading Review group. Br Med J 2001;323:334-6.
8. Tefferi A, Fonseca R, Pereira D, Hoagland C. A long-term retrospective study of young women with essential thrombocythemia. Mayo Clin Proc 2001;76:22-8.
9. Cortelazzo S, Viero P, Finazzi G, D'Emilio A, Rodeghiero F, Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 1990;8:556-62.
10. Besses C, Cervantes F, Pereira A, Florensa L, Sole F, Hernandez-Boluda JC, et al. Major vascular complications in essential thrombocythemia: a study of predictive factors in a series of 148 patients. Leukemia 1999;13:150-4.
11. Ruggeri M, Finazzi G, Tosetto A, Riva S, Rodeghiero F, Barbui T. No treatment for low-risk thrombocythaemia: results from a prospective study. Br J Haematol 1998;103:772-7.
12. Barbui T, Finazzi G, Dupuy E, Kiladjian JJ, Briere J. Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers. Leuk Lymphoma 1996;22 Suppl 1:149-60.
13. Randi ML, Luzzatto G, Fabris F. Low-risk essential thrombocythemia in patients younger than 40. Br J Haematol 1999;104:929.
14. Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995;332:1132-6.
15. Afshar-Kharghan V, Lopez JA, Gray LA, Padilla A, Borthakur G, Roberts SC, et al. Hemostatic gene polymorphisms and the prevalence of thrombohemorrhagic complications in polycythemia vera and essential thrombocythemia. Blood 2001;98:471a.
16. Dicato MA, Schroell B, Berchem GJ, Duhem C, Ries F, Mahon GA. V Leiden mutations, prothrombin and methylenetetrahydrofolate reductase are not risk factors for thromboembolic disease in essential thrombocythemia. Blood 1999;94:111a[abstract].
17. Ruggeri M, Gisslinger H, Tosetto A, Rintelen C, Mannhalter C, Pabinger I, et al. Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia. Am J Hematol 2002;71:1-6.
18. Jensen MK, de Nully Brown P, Thjorsen S, Hasselbalch HC. Frequent occurrence of anticardiolipin antibodies, Factor V Leiden mutation, and pertubed endothelial function in chronic myeloproliferative disorders. Am J Hematol 2002;69:185-91.
19. Harrison CN, Donohoe S, Carr P, Dave M, Mackie I, Machin SJ. Patients with essential thrombocythaemia have an increased prevalence of antiphospholipid antibodies which may be associated with thrombosis. Am J Hematol 2002;71:1-6.
20. Bucalossi A, Marotta G, Bigazzi C, Galieni P, Dispensa E. Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis. Am J Hematol 1996;52:14-20.
21. Faurschou M, Nielsen OJ, Jensen MK, Hasselbalch HC. High prevalence of the hyperhomocysteinemia due to marginal deficiency of cobalamin or folate in chronic myeloproliferative disorders. Eur J Haematol 2000;65:165-9.
22. Gisslinger H, Rodeghiero F, Ruggeri M, Heis-Vahidi Fard N, Mannhalter C, Papagiannopoulos M, et al. Homocysteine levels in polycythaemia vera and essential thrombocythemia. Br J Haematol 1999;105:551-5.
23. Jantunen R, Juvonen E, Ikkala E, Oksanen K, Anttila P, Ruutu T. The predictive value of vascular risk factors and gender for the development of thrombotic complications in essential thrombocythemia. Ann Hematol 2001;80:74-8.
24. Watson KV, Key N. Vascular complications of essential thrombocythaemia: a link to cardiovascular risk factors. Br J Haematol 1993;83:198-203.
25. Fenaux P, Simon M, Caulier MT, Lai JL, Goudemand J, Bauters F. Clinical course of essential thrombocythemia in 147 cases. Cancer 1990;66:549-56.
26. van Genderen PJ, Mulder PG, Waleboer M, van de Moesdijk D, Michiels JJ. Prevention and treatment of thrombotic complications in essential thrombocythaemia: efficacy and safety of aspirin. Br J Haematol 1997;97:179-84.
27. Hehlmann R, Jahn M, Baumann B, Kopcke W. Essential thrombocythemia. Clinical characteristics and course of 61 cases. Cancer 1988;61:2487-96.
28. Shih LY, Lin TL, Lai CL, Dunn P, Wu JH, Wang PN, et al. Predictive values of X-chromosome inactivation patterns and clinicohematologic parameters for vascular complications in female patients with essential thrombocythemia. Blood 2002;100:1596-601.
29. Harrison CN, Gale RE, Machin SJ, Linch DC. A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications. Blood 1999;93:417-24.
30. Chiusolo P, La Barbera EO, Laurenti L, Piccirillo N, Sora F, Giordano G, et al. Clonal hemopoiesis and risk of thrombosis in young female patients with essential thrombocythemia. Exp Hematol 2001;29:670-6.
31. Regev A, Stark P, Blickstein D, Lahav M. Thrombotic complications in essential thrombocythemia with relatively low platelet counts. Am J Hematol 1997;56:168-72.
32. van Genderen PJ, Budde U, Michiels JJ, van Strik R, van Vliet HH. The reduction of large von Willebrand factor multimers in plasma in essential thrombocythaemia is related to the platelet count. Ann Hematol 1994;69:81-4.
33. van Genderen PJ, Michiels JJ, van der Poelvan de Luytgaarde SC, van Vliet HH. Acquired von Willebrand disease as a cause of recurrent mucocutaneous bleeding in primary thrombocythemia: relationship with platelet count. Blood 1993;82:1749-57.
34. Finazzi G, Ruggeri M, Rodeghiero F, Barbui T. Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis. Blood 2003;101:3749.
35. Lofvenberg E, Wahlin A. Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea. Eur J Haematol 1988;41:375-81.
36. Murphy S, Iland H, Rosenthal D, Laszlo J. Essential thrombocythemia: an interim report from the Polycythemia Vera Study Group. Semin Hematol 1986;23:177-82.
37. Finazzi G, Ruggeri M, Rodeghiero F, Barbui T. Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. Br J Haematol 2002;116:923-4.
38. Geller SA, Shapiro E. Acute leukemia as a natural sequel to primary thrombocythemia. Am J Clin Pathol 1982;77:353-6.
39. Shibata K, Shimamoto Y, Suga K, Sano M, Matsuzaki M, Yamaguchi M. Essential thrombocythemia terminating in acute leukemia with minimal myeloid differentiation -a brief review of recent literature. Acta Haematol 1994;91:84-8.
40. Sterkers Y, Preudhomme C, Lai JL, Demory JL, Caulier MT, Wattel E, et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood 1998;91:616-22.
41. Randi ML, Fabris F, Girolami A. Second malignancies in patients with essential thrombocythaemia. Br J Haematol 2002;116:923.
42. Turlure P, Le Prise PY, Letortorec S. Essential thrombocythemia (ET) clinical course and results of a multicenter prospective study. Blood 1993;82 Suppl 1:1979.
43. Bernasconi P, Boni M, Cavigliano PM, Calatroni S, Brusamolino E, Passamonti F, et al. Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET): distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea. Leukemia 2002;16:2078-83.
44. Liu TC, Suri R. Multiple factors in the transformation of essential thrombocythemia to acute leukemia or myelodysplastic syndromes. Blood 1998;92:1465-6.
45. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 1995;332:1317-22.
46. Wilson S. Acute leukemia in a patient with sickle-cell anemia treated with hydroxyurea. Ann Intern Med 2000;133:925-6.
47. Colombi M, Radaelli F, Zocchi L, Maiolo AT. Thrombotic and hemorrhagic complications in essential thrombocythemia. A retrospective study of 103 patients. Cancer. 1991;67:2926-30.
48. Van de Pette JE, Prochazka AV, Pearson TC, Singh AK, Dickson ER, Wetherley-Mein G. Primary thrombocythaemia treated with busulphan. Br J Haematol 1986;62:229-37.
49. Cervantes F, Alvarez-Larran A, Talarn C, Gomez M, Montserrat E. Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients. Br J Haematol 2002;118:786-90.
50. Annaloro C, Lambertenghi Deliliers G, Oriani A, Pozzoli E, Lambertenghi Deliliers D, Radaelli F, et al. Prognostic significance of bone marrow biopsy in essential thrombocythemia. Haematologica 1999;84:17-21.
51. Patel M, Dukes IAF, Hull JC. Use of hydroxyurea in chronic myeloid leukemia during pregnancy: A case report. Am J Obstet Gynecol 1991;165:565-6.
52. Delmer A, Rio B, Bauduer F, Ajchenbaum F, Marie JP, Zittoun R. Pregnancy during myelosuppressive treatment for chronic myelogenous leukaemia. Br J Haematol 1992;82:783-4.
53. Tertian G, Tchernia G, Papiernik E, Elefant E. Hydroxyurea and pregnancy. Am J Obstet Gynecol 1992;166:1868.
54. Fitzgerald JM, McCann SR. The combination of hydroxyurea and leucapheresis in the treatment of chronic myeloid leukaemia in pregnancy. Clin Lab Haematol 1993;15:63-5.
55. Jackson N, Shukri A, Ali K. Hydroxyurea treatment for chronic myeloid leukaemia during pregnancy. Br J Haematol 1993;85:203-4.
56. Cinkotai KI, Wood P, Donnai P, Kendra J. Pregnancy after treatment with hydroxyurea in a patient with primary thrombocythaemia and a history of recurrent abortion. J Clin Pathol 1994;47:769-70.
57. Szanto F, Kovacs L. Successful delivery following continuous cytostatic therapy of a leukemic pregnant woman. Ovr Hetil 1994;134:527-9.
58. Dell'lsola A, De Rosa G, Catalano D. Essential thrombocythemia in pregnancy. A case report and general considerations. Minerva Ginecol 1997;49:165-72.
59. Diav-Citrin O, Hunnisett L, Sher GD, Koren D. Hydroxyurea usc during pregnancy: A case report in sickle cell disease and review of the literature. Am J Hematol 1999;60:148-50.
60. Griesshammer M, Bergmann L, Hafner M. Treatment and clinical course of essential thrombocythemia (ET): preliminary results of a prospective multicenter trial. Blood 1998;92 suppl 1:1750 (abstract).
61. Gisslinger H, Chott A, Scheithauer W, Gilly B, Linkesch W, Ludwig H. Interferon in essential thrombocythaemia. Br J Haematol 1991;79:42-7.
62. Pogliani EM, Rossini F, Miccolis I, Ferrario A, Perego D, Casaroli I, et al. α interferon as initial treatment of essential thrombocythemia. Analysis after two years of follow-up. Tumori 1995;81:245-8.
63. Lazzarino M, Vitale A, Morra E, Gagliardi A, Bernasconi P, Torromeo C, et al. Therapy of essential thrombocythemia with α-interferon: results and prospects. Eur J Haematol 1990;52 Suppl.: 15-21.
64. Giles FJ, Ozer H. α-Interferon in hematological malignancies. Curr Opin Biotechnol 1991;2:847-50.
65. Kasparu H, Bernhart M, Krieger O, Lutz D. Remission may continue after termination of rlFN α-2b treatment for essential thrombocythemia. Eur J Haematol 1992;48:33-6.
66. Middelhoff G, Boll I. A long-term clinical trial of interferon alpha-therapy in essential thrombocythemia. Ann Hematol 1992;64:207-9.
67. Rametta V, Ferrara F, Marottoli V, Matera C, Mettivier V, Cimino R. Recombinant interferon α-2b as treatment of essential thrombocythaemia. Acta Haematol 1994;91:126-9.
68. Golub RM, Dave S, Adams JR, et al. The cost-effectiveness of therapeutic options for essential thrombocythemia. Blood 2001;98 Suppl 1:1787[abstract].
69. Abegg-Werter MJ, Raemaekers JM, de Pauw BE, Haanen C. Recombinant interferon-α, but not interferon-γ is effective therapy for essential thrombocythemia. Blut 1990;60:37-40.
70. Merup M, Tornebohm-Roche E, Engman K, Paul C. Human leucocyte interferon-α therapy can induce a second response in treatment of thrombocytosis in patients with neutralising antibodies to recombinant interferon-α2a. Eur J Cancer 1994;30A:1729-30.
71. Gugliotta L, Bulgarelli S, Vianelli N, Russo D, Gamberi B, Candoni A, et al. PEG Interferon α-2b (Peg Intron) in essential thrombocythemia. Blood 2002;100 Suppl 1:3150[abstract].
72. Mazzucconi MG, De Sanctis V, Chistolini A, Dragoni F, Mandelli F. Therapy with anagrelide in patients affected by essential thrombocythemia: preliminary results. Haematologica 1992;77:315-7.
73. Petrides PE, Beykirch MK, Trapp OM. Anagrelide, a novel platelet lowering option in essential thrombocythaemia: treatment experience in 48 patients in Germany. Eur J Haematol 1998;61:71-6.
74. Mills AK, Taylor KM, Wright SJ, Bunce I, Eliadis P, Brigden MC, et al. Efficacy, safety and tolerability of anagrelide in the treatment of essential thrombocythaemia. Aust N Z J Med 1999;29:29-35.
75. Laguna MS, Kornblihtt LI, Marta RF, Michiels JJ, Molinas FC. Effectiveness of anagrelide in the treatment of symptomatic patients with essential thrombocythemia. Clin Appl Thromb Hemost 2000;6:157-61.
76. Silverstein MN, Petitt RM, Solberg LA Jr, Fleming JS, Knight RC, Schacter LP. Anagrelide: a new drug for treating thrombocytosis. N Engl J Med 1988;318:1292-4.
77. Anagrelide Study Group. Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Am J Med 1992;92:69-76.
78. Balduini CL, Bertolino G, Noris P, Ascari E. Effect of anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferative disorders. Haematologica 1992;77:40-3.
79. Petitt RM, Silverstein MN, Petrone ME. Anagrelide for control of thrombocythemia in polycythemia and other myeloproliferative disorders. Semin Hematol 1997;34:51-4.
80. Storen EC, Tefferi A. Long-term use of anagrelide in young patients with essential thrombocythemia. Blood 2001;97:863-6.
81. Chintagumpala MM, Kennedy LL, Steuber CP. Treatment of essential thrombocythemia with anagrelide. J Pediatr 1995;127:495-8.
82. Brusamolino E, Canevari A, Salvaneschi L, Merante S, Bernasconi C. Efficacy trial of pipobroman in essential thrombocythemia: a study of 24 patients. Cancer Treat Rep 1984;68:1339-42.
83. Passamonti F, Malabarba L, Orlandi E, Pascutto C, Brusamolino E, Astori C, et al. Pipobroman is a safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis. Br J Haematol 2002;116:855-61.
84. Mazzucconi MG, Francesconi M, Chistolini A, Falcione E, Ferrari A, Tirindelli MC, et al. Pipobroman therapy of essential thrombocythemia. Scand J Haematol 1986;37:306-9.
85. Chistolini A, Mazzucconi MG, Ferrari A, la Verde G, Ferrazza G, Dragoni F, et al. Essential thrombocythemia: a retrospective study on the clinical course of 100 patients. Haematologica 1990;75:537-40.
86. Van de Pette JE, Prochazka AV, Pearson TC, Singh AK, Dickson ER, Wetherley-Mein G. Primary thrombocythaemia treated with busulphan. Br J Haematol 1986;62:229-37.
87. Berrebi A, Shvidel L, Shtalrid M, Klepfish A. Short course of busulphan in essential thrombocythaemia: remodelling of an old strategy. Br J Haematol 2000;109:249-50.
88. Michiels JJ. Normal life expectancy and thrombosis-free survival in aspirin treated essential thrombocythemia. Clin Appl Thromb Hemost 1999;5:30-6.
89. Murphy S, Rosenthal DS, Weinfeld A, Briere J, Faguet GB, Knospe WH, et al. Essential thrombocythemia: response during first year of therapy with melphalan and radioactive phosphorus: a Polycythemia Vera Study Group report. Cancer Treat Rep 1982;66:1495-500.
90. Gris JC, Schved JF, Arnaud A, Chauvet C. Myelodysplastic syndrome and secondary acute leukemia after treatment of essential thrombocythemia with melphalan. Am J Hematol 1989;30:47-8.
91. de Pauw BE, van Bergen AN, Haanen C, Steenbergen J. Intermittent melphalan in the treatment of essential thrombocytosis with haemorrhage or thrombosis. Scand J Haematol 1985;35:448-50.
92. Murphy S, Peterson P, Iland H, Laszlo J. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 1997;34:29-39.
93. Wagner S, Waxman J, Sikora K. The treatment of essential thrombocythaemia with radioactive phosphorus. Clin Radiol 1989;40:190-2.
94. Randi ML, Fabris F, Varotto L, Rossi C, Macri C, Girolami A. Haematological complications in polycythaemia vera and thrombocythaemia patients treated with radiophosphorus (32P). Folia Haematol Int Mag Klin Morphol Blutforsch 1990;117:461-7.
95. Balan KK, Critchley M. Outcome of 259 patients with primary proliferative polycythemia (PPP) and idiopathic thrombocythemia (IT) treated in a regional nuclear medicine department with phosphorus-32 - a 15 year review. Br J Radiol 1997;70:1169-73.
96. Brandt L, Anderson H. Survival and risk of acute leukemia in polycythemia vera and essential thrombocythemia treated with oral phosphorus safer dugs available. Eur J Haematol 1995;54:21-6.
97. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994;330:1287-94.
98. Koudstaal PJ, Koudstaal A. Neurologic and visual symptoms in ET: efficacy of low dose aspirin. Sem Thromb Hemost 1997;23:365-70.
99. Van Genderen PJJ, Mukder PGH, Waleboer M, van de Moesdijk D, Michies JJ. Prevention and treatment of thrombotic complications in essential thrombocythemia: efficacy and safety of aspirin. Br J Haematol 1997;97:179-84.
100. Randi ML, Rossi C, Fabris F, Menapace L, Girolami A. Aspirin seems as effective as myelosuppressive agents in the prevention of rethrombosis in essential thrombocythemia. Clin Appl Thromb Hemost 1999;5:131-5.
101. Landolfi R, Patrono C. Aspirin in polycythemia vera and essential thrombocythemia: current facts and perspectives. Leuk Lymphoma 1996;22 Suppl 1:83-6.
102. Rocca B, Ciabattoni G, Tartaglione R, Cortelazzo S, Barbui T, Patrono C, et al. Increased thromboxane biosynthesis in essential thrombocythemia. Thromb Haemost 1995;74:1225-30.
103. Fitzmaurice DA, Blann AD, Lip GY. Bleeding risks of antithrombotic therapy. BMJ. 2002;325:828-31.
104. Michiels JJ, Abels J, Steketee J, van Vliet HH, Vuzevski VD. Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. Ann Intern Med 1985;102:466-71.
105. Griesshammer M, Bangerter M, van Vliet HH, Michiels JJ. Aspirin in essential thrombocythemia: status quo and quo vadis. Semin Thromb Hemost 1997;23:371-7.
106. Ruggeri M, Castaman G, Rodeghiero F. Is ticlopidine a safe alternative to aspirin for management of myeloproliferative disorders? Haematologica 1993;78 Suppl 2:18-21.
107. Hirsh J, Dalen J, Guyatt G. The sixth (2000) ACCP guidelines for antithrombotic therapy for prevention and treatment of thrombosis. American College of Chest Physicians. Chest 2001;119 Suppl 1:1S-2S.
108. Spilberg O, Shimon I, Sofer O, Dolitski M, Ben-Bassat I. Transient normal platelet counts and decreased requirement for interferon during pregnancy in essential thrombocythaemia. Br J Haematol 1996;92:491-3.
109. McColl MD, Ramsay JE, Tait RC, Walker ID, McCall F, Conkie JA, et al. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost 1997;78:1183-8.
110. Wright CA, Tefferi A. A single institutional experience with 43 pregnancies in essential thrombocythemia. Eur J Haematol 2001;66:152-9.
111. Radin AI, Kim HT, Grant BW, Bennett JM, Kirkwood JM, Stewart JA, et al. Phase II study of α2 interferon in the treatment of the chronic myeloproliferative disorders (E5487): a trial of the Eastern Cooperative Oncology Group. Cancer 2003;98:100-9.
112. Tsimberidou AM, Colburn DE, Welch MA, Cortes JE, Verstovsek S, O'Brien SM, et al. Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders. Cancer Chemother Pharmacol 2003;52:229-34.
113. Alvarado Y, Cortes J, Verstovsek S, Thomas D, Faderl S, Estrov Z, et al. Pilot study of pegylated interferon-α 2b in patients with essential thrombocythemia. Cancer Chemother Pharmacol 2003;51:81-6.
114. Nielsen I, Hasselbalch HC. Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. Am J Hematol 2003;74:26-31.